


PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)



(51) International Patent Classification ⁶ : A61K 48/00		(11) International Publication Number: WO 99/61069
A1		(43) International Publication Date: 2 December 1999 (02.12.99)
(21) International Application Number: PCT/US99/12201		(81) Designated States: AE, AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, UZ, VN, YU, ZA, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
(22) International Filing Date: 1 June 1999 (01.06.99)		
(30) Priority Data: 09/086,651 29 May 1998 (29.05.98) US		
(71) Applicant: UNIVERSITY OF FLORIDA [US/US]; 223 Grinter Hall, Gainesville, FL 32611 (US).		
(72) Inventors: MOYER, Richard, W.; 1225 N.W. 23rd Terrace, Gainesville, FL 32605 (US); LI, Yi; Universite du Quebec, Institut Armand-Frappier, 531, boulevard des Prairies, Case Postale 100, Laval, Quebec H7N 4Z3 (CA).		
(74) Agents: SALIWANCHIK, David, R. et al.; Saliwanchik, Lloyd & Saliwanchik, Suite A-1, 2421 N.W. 41st Street, Gainesville, FL 32606-6669 (US).		<p>Published</p> <p><i>With international search report.</i></p> <p><i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>

(54) Title: MATERIALS AND METHODS FOR DELIVERY AND EXPRESSION OF HETEROLOGOUS DNA IN VERTEBRATE CELLS



(57) Abstract

The subject invention pertains to recombinant entomopox vectors which are useful for the delivery and stable expression of heterologous DNA in vertebrate cells. Specifically exemplified is a recombinant EPV from *amsacta moorei* (AmEPV). Because of the capacity of the EPV to incorporate foreign or heterologous DNA sequences, the vectors of the subject invention can be used to deliver DNA inserts that are larger than 10 kb in size. Accordingly, one aspect of the present invention concerns use of the recombinant vectors for delivery and expression of biological useful proteins in gene therapy protocols.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

DESCRIPTIONMATERIALS AND METHODS FOR DELIVERY AND EXPRESSION OF
HETEROLOGOUS DNA IN VERTEBRATE CELLS

5

The subject invention was made with government support under a research project supported by U.S. Department of Agriculture Grant No. 97-35302-4431 and National Institute of Health Grant No. P50-HL59412-01. The government has certain rights in this invention.

10

Background of the Invention

Gene therapy is a powerful concept just now beginning to see applications designed to treat human diseases such as genetic disorders and cancer. The introduction of genes into an organism can be achieved in a variety of ways including virus based vectors. Viral gene therapy vectors can either be designed to deliver and express genes permanently (stable integration of a foreign gene into host chromosome) or transiently (for a finite period of time).

15

20

Current virus-based gene transfer vectors, are typically derived from animal viruses, such as retroviruses, herpesviruses, adenoviruses, or adeno-associated viruses. Generally, these viruses are engineered to remove one or more genes of the virus. These genes may be removed because they are involved in viral replication and/or to provide the capacity for insertion and packaging of foreign genes. Each of these known vectors has some unique advantages as well as disadvantages. One primary disadvantage is an inability to readily package and deliver large DNA inserts that are greater than 10 kb in size.

25

30

To illustrate the problem of capacity of most gene therapy vectors, one need only consider adeno-associated virus (AAV), one of the most promising of the gene therapy vectors. Adeno-associated virus (AAV) is a parvovirus which consists of a 4.7 kb single stranded DNA genome (Nienhuis *et al.*, 1983). The viral genome consists of the family of *rep* genes responsible for regulatory function and DNA replication and the *cap* genes that encode the capsid proteins. The AAV coding region is flanked by 145 nucleotide inverted terminal repeat (ITR) sequences which are the minimum cis-acting elements

essential for replication and encapsidation of the genome. In the absence of a helper virus such as adenovirus, AAV causes a latent infection characterized by the integration of viral DNA into the cellular genome. The major advantages of recombinant AAV (rAAV) vectors include a lack of pathogenicity in humans (Berns and Bohenzky, 1987),
5 the ability of wild-type AAV to integrate stably into the long arm of chromosome 19 (Kotin *et al.*, 1992), the potential ability to infect nondividing cells (Kaplitt *et al.*, 1994), and broad range of infectivity. However, the packaging capacity of AAV limits the size of the inserted heterologous DNA to about 4.7 kb.

Gene therapy vector systems are also needed that combine a large carrying
10 capacity with high transduction efficiency *in vivo*. We describe here a new gene delivery system which has a large capacity for insertion of foreign genes and which integrates stably into host chromosome.

Entomoxpoxvirus (EPVs) productively infect and kill only insects (Granados, 1981) and can be isolated from *Amsacta moorei* (AmEPV), the red hairy caterpillar.
15 Entomopox viruses and vectors have been described (See, for example, U.S. Patent Nos. 5,721,352 and 5,753,258, the disclosure of which is incorporated herein by reference). Like other EPVs, AmEPV cannot productively infect vertebrate cells. Indeed, following addition of AmEPV to vertebrate (mouse L-929) cells at multiplicities up to 10 particles/cell, no changes in cellular morphology (as judged by phase contrast
20 microscopy) are detected (Langridge, 1983).

AmEPV infects vertebrate cells in a non-cytocidal manner and the infection is abortive. Like all poxviruses, the virus is cytoplasmic and does not normally enter the nucleus. A consequence of this unusual biology, is that all poxvirus mediated gene
25 expression takes place in the cytoplasm in the infected cell. AmEPV promoters and those of the eucaryotic cell are completely different and cellular promoters are not recognized by the AmEPV transcription machinery nor are AmEPV viral promoters recognized by RNA polymerase II of the host cell.

Brief Summary of the Invention

30 The subject invention concerns a novel viral vector system for gene therapy based on an insect poxvirus designed to deliver genes for integration and stable, permanent expression in vertebrate cells. In an exemplified embodiment, a recombinant AmEPV

vector was constructed that contains heterologous genes under the control of promoters that drive expression of the heterologous genes in vertebrate cells. The *gfp* gene and the gene encoding G418 resistance were used in an exemplified construct. The recombinant AmEPV was used to infect vertebrate cells and following infection the cells were transferred to media containing G418. Cells expressing both GFP and G418 resistance were obtained. Thus, the vectors of the subject invention can be used to deliver large DNA segments for the engineering of vertebrate cells.

The subject invention also concerns cells that have been infected with or transformed with a recombinant vector of the present invention. The subject invention also concerns methods for providing gene therapy for conditions or disorders of an animal requiring therapy, such as genetic deficiency disorders.

Brief Description of the Drawings

Figure 1 shows a physical map of an exemplified recombinant vector of the subject invention (pAmEPV TKUF5) in which a portion of the plasmid pTKUF5 has been cloned within the AmEPV TK gene flanking regions. TR is the AAV terminal repeat, pA is a polyadenylation site, SD/SA is the SV40 late splice donor, splice acceptor sequence. GFP is under the control of a CMB promoter, Neo is under the control of a herpes TK gene promoter.

Detailed Disclosure of the Invention

The subject invention concerns novel recombinant vectors and methods for delivery and expression of heterologous polynucleotides in vertebrate cells. The recombinant vectors of the subject invention provide for stable integration and expression of heterologous DNA in the host cell. Advantageously, the vectors of the invention are adapted for accepting large heterologous polynucleotide inserts which can be delivered and stably expressed in an infected or transformed cell. The subject invention can be used to provide gene therapy for conditions or disorders of vertebrate animals, such as a mammal or human, that is in need of such therapy.

One aspect of the subject invention concerns a recombinant EPV vector which can optionally include heterologous DNA which can be expressed in a cell infected or transformed with the subject vector. Preferably, the EPV vector is derived from AmEPV.

The recombinant EPV vectors of the present invention can optionally include inverted terminal repeat (ITR) sequences of a virus, such as, for example, adeno-associated virus, that flank the heterologous DNA insertion site on the vector. Thus, when the heterologous DNA is cloned into the recombinant EPV vector, the heterologous DNA is flanked upstream and downstream by the ITR sequences.

In an exemplified embodiment, the subject vectors comprise heterologous DNA inserted within the vector. The heterologous DNA contained within the recombinant vectors of the invention can include polynucleotide sequences which encode a biologically functional protein. Preferably, the polynucleotides encode proteins which can provide therapeutic replacement or supplement in animals afflicted with disorders which result in the animal expressing abnormal or deficient levels of the protein that are required for normal biological function. Proteins encoded by the heterologous DNA can include, but are not limited to interleukins, cytokines, growth factors, interferons, enzymes, and structural proteins. Protein encoded by the heterologous DNA can also include proteins that provide a selectable marker for expression, such as antibiotic resistance in eucaryotes.

In a preferred embodiment, heterologous DNA within the subject vectors is operably linked with and under the control of regulatory sequences, such as promoters. The recombinant vectors of the invention preferably comprises a constitutive or regulatable promoter capable of promoting sufficient levels of expression of the heterologous DNA contained in the viral vector in a vertebrate cell. Promoters useful with the subject vectors include, for example, the cytomegalovirus (CMV) promoters and the herpes TK gene promoter. The vectors can also include other regulatory elements such as introns inserted into the polynucleotide sequence of the vector.

The subject invention also concerns cells containing recombinant vectors of the present invention. The cells can be, for example, vertebrate cells such as mammalian cells. Preferably, the cells are human cells. Cell lines infected or transformed with the recombinant vectors of the present invention are also within the scope of the invention.

The recombinant vectors of the present invention can be introduced into suitable cells or cell lines by methods known in the art. If the recombinant vectors are packaged in viral particles then cells or cell lines can be infected with the virus containing the recombinant vector. Methods contemplated for introducing recombinant vector into cells

or cell lines also include transfection, transduction and injection. For example, vectors can be introduced into cells using liposomes containing the subject recombinant vectors. Recombinant viral particles and vectors of the present invention can be introduced into cells by *in vitro* or *in vivo* means.

5 Infection of vertebrate cells is non-permissive, and that early but not late AmEPV gene expression occurs (Li *et al.*, 1997). Specifically, if a reporter gene, such as *lacZ* is driven by a late poxvirus promoter, either the AmEPV spheroidin or cowpox virus ATI (A-type Inclusion) promoter, no expression of galactosidase is observed. If, however, the *lacZ* is driven instead by either of two early EPV promoters (the *Melolontha*
10 *melolontha* EPV fusolin gene promoter (Gauthier *et al.*, 1995) or the 42 kDa early AmEPV protein (Li *et al.*, 1997)), high levels of galactosidase in the recombinant AmEPV infected vertebrate cells are observed. These results provide clear evidence of AmEPV entry into vertebrate cells followed by early, but not late, viral gene expression.

 It has also been found that vertebrate cells survive infection by AmEPV. If CV-1
15 cells are infected with an AmEPV recombinant which contains the green fluorescent protein (*GFP*) gene regulated by the 42 kDa AmEPV early promoter (also called the *esp* promoter), single, fluorescent cells are initially observed which then proceed to grow and divide, ultimately forming small clusters of fluorescent cells. Therefore, AmEPV enters vertebrate cells, to produce a non-permissive, abortive infection, early viral genes are
20 expressed and infected cells appear to survive and continue to divide. These properties plus a very large capacity of the virus for foreign genes make AmEPV an excellent vector for delivery of genes for expression in a transient fashion.

Materials and Methods

25 Cells and virus.

 AmEPV (Hall and Moyer, 1991) was replicated in IPLB-LD-652 cells (Goodwin
et al., 1990) which were maintained at 28°C in a 1:1 mixed medium (TE medium) of TC-100 media (Gibco, Gaithersburg, MD) and EX-CELL 401 media (JRH Biosciences, Lenexa, KS), supplemented with 10% fetal bovine serum. A TK negative cell line
30 designated C11.3 was selected by a process of adaption of TK(+) LD652 cell to increasing levels, 10 µg/ml every 5 weeks, of 5-bromo-2'-deoxyuridine (BudR) over one

year up to 100 μ g/ml BudR and maintained in TE medium containing BudR (100 μ g/ml). 293 cells were grown in DMEM medium supplemented with 5% fetal bovine serum.

Plasmid construction and preparation of AmEPV recombinant.

5 pTR-UF5 (see Figure 1, provided by the Vector Core, Gene Therapy Center, University of Florida) contains GFP and NeoR genes under control GMV promoter and herpes virus TK promoter respectively and flanked by ITR sequences of AAV. The Pst I fragment which contains GFP and NeoR markers was inserted into Pst I site of pTKDU (Li *et al.*, 1998) to produce pTKUF5. AmEPV recombinant with an insert in the TK gene
10 was obtained as described previously (Li *et al.*, 1998).

Following are examples which illustrate procedures for practicing the invention. These examples should not be construed as limiting. All percentages are by weight and all solvent mixture proportions are by volume unless otherwise noted.

15

Example 1 — Gene expression in cells infected with recombinant AmEPV

293 cells (1×10^6) were placed in 6-well plate and infected with recombinant AmEPVpTKUF5 or AmEPVpTKespgfp (Li *et al.*, 1997) viruses at a multiplicity of five (5) virus particles/cell. As controls, cells were separately transfected with either the
20 plasmid pTR-UF5 or pTKUF5 at a 5 μ g/well plasmid DNA. Two days later, virus infected or plasmid transfected cells were transferred into 60 mm dishes, after 24 hr, neomycin resistant colonies were selected by adding G418 at the final concentration of 200 μ g/ml. G418 containing medium was changed every 3-4 days.

For cells infected with recombinant AmEPV pTKespgfp, no neomycin resistant
25 colony was observed, an expected result since this virus does not have NeoR gene. However, cells infected with recombinant AmEPV pTKUF5 or transfected with plasmids pTR-UF5, G418 resistant colonies were observed. All colonies from cells transfected with either of the two plasmids were both G418 resistant and GFP positive. However, colonies from cells infected with recombinant pTKUF5 were initially only G418
30 resistant, and not GFP positive. G418 resistant colonies derived from the AmEPV recombinant also grew more slowly than those produced following plasmid transfection. Most likely, the explanation for these results is that GFP and NeoR gene copy number

in AmEPV derived colonies is less than those transfected with plasmids. This explanation is likely to be true as we were able to show that the AmEPV derived colonies gradually become more and more resistant to G418 and soon, some GFP positive clusters of cells were observed which become more numerous and brighter. After several
5 changes of medium, ultimately, all cells in the well were GFP positive.

It should be understood that the examples and embodiments described herein are for illustrative purposes only and that various modifications or changes in light thereof will be suggested to persons skilled in the art and are to be included within the spirit and
10 purview of this application and the scope of the appended claims.

ReferencesU.S. Patents

U.S. Patent No. 5,721,352

U.S. Patent No. 5,753,258

Other References

Berns, K.I. and R.A. Bohenzky (1987) "Adeno-associated viruses: an update. *Adv. Virus Res.* 32:243-306.

Gauthier, L., F. Coussrans, J.C. Veyrunes, M. Bergoin (1995) "The *Melolontha melolontha* entomopoxvirus (MmEPV) fusolin is related to the fusolins of lepidoptera EPVs and to the 37 K baculovirus glycoprotein" *Virology* 208:427-436.

Granados, R.R. (1981) "Entomopoxvirus infections in insects. In Pathogenesis of invertebrate Microbial Disease, p. 102-126. Davidson, E.W. (ed.) New Jersey, Allanheld Totowa.

Kaplitt *et al.* (1994) "Long term gene expression and phenotypic correction using adeno- associated virus vectors in the mammalian brain" *Nat. Genet* 8:148-154.

Kotin, R.M., R.M. Linden, K.I. Berns (1992) "Characterization of a preferred site on human chromosome 10q for integration of adeno-associated virus DNA by nonhomologous recombination" *EMBO J* 11:5071-5078.

Langridge, W.H. (1983) "Detection of *Amsacta moorei* entomopoxvirus and vaccinia virus proteins in cell cultures restrictive for poxvirus multiplication" *J. Invertebr. Pathol.* 42:77-82.

Li, Y., R.L. Hall, R.W. Moyer (1997) "Transient, nonlethal expression of genes in vertebrate cells by recombinant entomopoxviruses" *J. Virol.* 71:9557-9562.

Li, Y., R.L. Hall, S.L. Yuan, R.W. Moyer (1998) "High level expression of *Amsacta moorei* entomopoxvirus *Spheroidin* depends on sequences within the gene" *J. Gen. Virol.* 79:613-622.

Nienhuis, A.W., C.E. Walsh, J.M. Liu (1993) "Viruses as therapeutic gene transfer vectors" In: N.S. Young (ed.) *Viruses and bone marrow*, Marcel Dekker, New York, p353-414.

Claims

- 1 1. A method for providing a vertebrate animal with a therapeutically effective
2 amount of a protein, said method comprising introducing into cells of said animal an
3 effective amount of a recombinant entomopox vector, wherein said vector comprises a
4 polynucleotide encoding said protein.
- 1 2. The method according to claim 1, wherein said animal is a mammal.
- 1 3. The method according to claim 2, wherein said animal is a human.
- 1 4. The method according to claim 1, wherein said vector comprises inverted
2 terminal repeat sequences flanking said polynucleotide encoding said protein.
- 1 5. The method according to claim 4, wherein said inverted terminal repeat
2 sequences are derived from adeno-associated virus.
- 1 6. The method according to claim 1, wherein said vector comprises a promoter
2 sequence capable of driving expression of said polynucleotide encoding said protein.
- 1 7. The method according to claim 7, wherein said promoter sequences are
2 selected from the group consisting of CMV promoter sequences and herpes TK promoter
3 sequences.
- 1 8. The method according claim 1, wherein said protein encoded by said
2 polynucleotide is selected from the group consisting of interleukins, cytokines, growth
3 factors, interferons, enzymes and structural proteins.
- 1 9. The method according to claim 1, wherein said vector is introduced into said
2 cells of said animal by infection in a viral particle.

1 10. The method according to claim 1, wherein said vector is introduced into said
2 cells of said animal by means selected from the group consisting of transfection,
3 transduction and injection.

1 11. The method according to claim 1, wherein said vector is introduced into said
2 cells of said animal *in vitro* and said treated cells are introduced into said animal.

1 12. The method according to claim 1, wherein said vector is introduced into said
2 cells of said animal *in vivo*.

1 13. The method according to claim 1, wherein said polynucleotide encoding said
2 protein is greater than about 10 kb in size.

1 14. The method according to claim 1, wherein said polynucleotide also encodes
2 a selectable marker protein.

1 15. A recombinant entomopox virus vector comprising a polynucleotide
2 encoding a protein capable of providing a therapeutic effect to an animal when expressed
3 in said animal.

1 16. The recombinant vector according to claim 15, wherein said animal is a
2 mammal.

1 17. The vector according to claim 16, wherein said mammal is a human.

1 18. The vector according to claim 15, wherein said entomopox virus is *Amsacta*
2 *moorei*.

1 19. The vector according to claim 15, wherein said vector comprises inverted
2 terminal repeat sequences flanking said polynucleotide encoding said protein.

1 20. The vector according to claim 19, wherein said inverted terminal repeat
2 sequences are derived from adeno-associated virus.

1 21. The vector according to claim 15, wherein said vector comprises a promoter
2 sequence capable of driving expression of said polynucleotide encoding said protein.

1 22. The vector according to claim 21, wherein said promoter sequences are
2 selected from the group consisting of CMV and herpes TK.

1 23. The vector according to claim 15, wherein said protein encoded by said
2 polynucleotide is selected from the group consisting of interleukins, cytokines, growth
3 factors, interferons, enzymes and structural proteins.

1 24. The vector according to claim 15, wherein said polynucleotide encoding said
2 protein is greater than about 10 kb in size.

1 25. The vector according to claim 15, wherein said polynucleotide also encodes
2 a selectable marker protein.

1 26. A viral particle comprising the vector of claim 15.

1 27. A cell comprising the vector of claim 15.

1 28. The cell according to claim 27, wherein said cell expresses a protein encoded
2 by said polynucleotide.

1/1




FIG. 1

INTERNATIONAL SEARCH REPORT

International Application No.

PC./US 99/12201

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 A61K48/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X,P	WO 98 50571 A (UNIV FLORIDA) 12 November 1998 (1998-11-12) page 4, line 14 -page 6, line 5 ---	1
A	WO 94 13812 A (UNIV FLORIDA :MOYER RICHARD W (US); HALL RICHARD L (US); GRUIDL MI) 23 June 1994 (1994-06-23) ---	
A	US 5 721 352 A (HALL RICHARD L ET AL) 24 February 1998 (1998-02-24) cited in the application -----	



Further documents are listed in the continuation of box C



Patent family members are listed in annex

* Special categories of cited documents

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

& document member of the same patent family

Date of the actual completion of the international search

24 September 1999

Date of mailing of the international search report

01/10/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel: (+31-70) 340-2040, Tx 31 651 epo nl
Fax: (+31-70) 340-3016

Authorized officer

Rempp, G

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 99/12201

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 1-14
because they relate to subject matter not required to be searched by this Authority, namely:

see FURTHER INFORMATION sheet PCT/ISA/210
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International Application No. PCT/US 99 /2201

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.1

Although claims 1-14 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

Continuation of Box I.1

Claims Nos.: 1-14

Rule 39.1(iv) PCT - Method for treatment of the human or animal body by therapy

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PC./US 99/12201

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9850571	A	12-11-1998	AU 7372498 A	27-11-1998
WO 9413812	A	23-06-1994	US 5476781 A	19-12-1995
			AU 5847194 A	04-07-1994
			US 5935777 A	10-08-1999
US 5721352	A	24-02-1998	AU 663709 B	19-10-1995
			AU 1663492 A	15-09-1992
			CA 2103550 A	20-08-1992
			EP 0573613 A	15-12-1993
			JP 6506594 T	28-07-1994
			MX 9200697 A	01-03-1993
			NZ 241662 A	28-03-1995
			WO 9214818 A	03-09-1992
			US 5935777 A	10-08-1999
			US 5476781 A	19-12-1995
			CN 1065293 A	14-10-1992